Upper gastrointestinal tumors: Current status and future perspectives

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 975-991

  Jiang, Yixing ^a   Kimchi, Eric T ^b   Staveley O'Carroll, Kevin F ^a   Montero, Alberto J ^c   Ajani, Jaffer A ^d  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Current treatment approaches; Esophageal cancer; Gastric cancer; Hepatocellular cancer; Pancreatic cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OMEPRAZOLE; OXALIPLATIN; PLACEBO; SORAFENIB; STREPTOZOCIN; SUNITINIB;

ADJUVANT THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; RADIOFREQUENCY ABLATION; REVIEW; STOMACH CANCER; SURGICAL APPROACH; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ESOPHAGUS TUMOR; LIVER TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; STOMACH TUMOR; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 47249129100     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.975     Document Type: Review

References (201)

1. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest. Endosc. 67(3), 394-398 (2008).
2. Rudolph RE, Vaughan TL, Storer BE et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann. Intern. Med. 132(8), 612-620 (2000).
3. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 95(12), 3383-3387 (2000).
4. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53(8), 1070-1074 (2004).
5. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 94(12), 3413-3419 (1999).
6. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin. Surg. Oncol. 13(4), 270-280 (1997).
7. Spechler SJ. Clinical practice. Barrett's Esophagus. N. Engl. J. Med. 346(11), 836-842 (2002).
8. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. Aii overrated risk? Gastroenterology 87(4), 927-933 (1984).
9. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359(9319), 1727-1733 (2002).
10. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann. Surg. 234(4), 520-531 (2001).
11. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J. Clin. Oncol. 25(26), 4110-4117 (2007).
12. Hasegawa N, Niwa Y, Arisawa T, Hase S, Goto H, Hayakawa T. Preoperative staging of superficial esophageal carcinoma: comparison of an ultrasound probe and standard endoscopic ultrasonography. Gastrointest. Endosc. 44(4), 388-393 (1996).
13. Kawano T, Ohshima M, Iwai T. Early esophageal carcinoma: endoscopic ultrasonography using the Sonoprobe. Abdom. Imaging 28(4), 477-485 (2003).
14. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J. Clin. Oncol. 23(20), 4483-4489 (2005).
15. Nesje LB, Svanes K, Viste A, Laerum OD, Odegaard S. Comparison of a linear miniature ultrasound probe and a radial-scanning echoendoscope in TN staging of esophageal cancer. Scand. J. Gastroenterol. 35(9), 997-1002 (2000).
16. Vazquez-Sequeiros E, Wiersema MJ. High-frequency US catheter-based staging of early esophageal tumors. Gastrointest. Endosc. 55(1), 95-99 (2002).
17. Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastrooesophageal junction cancer. Int. J. Surg. 5(6), 399-403 (2007).
18. Malik V, Keogan M, Gilham C, Duffy G, Ravi N, Reynolds JV. FDG-PET scanning in the management of cancer of the oesophagus and oesophagogastric junction: early experience with 100 consecutive cases. Ir. J. Med. Sci. 175(4), 48-54 (2006).
19. Meyers BF, Downey RJ, Decker PA et al. American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J. Thorac. Cardiovasc. Surg. 133(3), 738-745 (2007).
20. Giovannini M, Bories E, Pesenti C et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 36(9), 782-787 (2004).
21. May A, Gossner L, Pech O et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE), curative treatment using local endoscopic treatment techniques. Endoscopy 34(8), 604-610 (2002).
22. Panjehpour M, Overholt BF. Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia. Lasers Surg. Med. 38(5), 390-395 (2006).
23. Seewald S, Akaraviputh T, Seitz U et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest. Endosc. 57(7), 854-859 (2003).
24. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized Phase III trial. Gastrointest. Endosc. 62(4), 488-498 (2005).
25. Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest. Endosc. 62(1), 24-30 (2005).
26. Pech O, May A, Gossner L et al. Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Edoscopy 39(1), 30-35 (2007).
27. Edwards MJ, Gable DR, Lentsch AB, Richardson JD. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann. Surg. 223(5), 585-591 (1996).
28. Williams VA, Watson TJ, Herbella FA et al. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J. Gastrointest. Surg. 11(12), 1589-1597 (2007).
29. Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br. J. Surg. 87(8), 1102-1105 (2000).
30. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br. J. Surg. 80(3), 367-370 (1993).
31. Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N. Engl. J. Med. 347(21), 1662-1669 (2002).
32. Ando N, Iizuka T, Ide H et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J. Clin. Oncol. 21(24), 4592-4596 (2003).
33. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J. Thorac. Cardiovasc. Surg. 114(2), 205-209 (1997).
34. Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O. 5-fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann. Surg. 223(2), 127-133 (1996).
35. Armanios M, Xu R, Forastiere AA, Haller DG, Kugler JW, Benson AB III. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastroesophageal junction, and cardia: Phase II trial (E8296) of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(22), 4495-4499 (2004).
36. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 339(27), 1979-1984 (1998).
37. Kok T, van Lanschot J, Siersema P, van Overhagen H, Tilanus H. Neoadjuvantchemotherapy in operable esophageal squamous cell cancer: final report of a Phase III multicenter randomized controlled trial. Proc. Am. Soc. Clin. Oncol. 16, 984 (1997) (Abstract).
38. Law S, Fok M, Chow S. Chu KM, Wong J. Preoperativie chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J. Thorac. Cardiovasc. Surg. 114(2), 210-217 (1997).
39. Maipang T, Vasinanukorn P, Petpichetchian C et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J. Surg. Oncol. 56(3), 191-197 (1994).
40. Nygaard K, Hagen S, Hansen HS et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J. Surg. 16(6), 1104-1110 (1992).
41. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J. Thorac. Cardiovasc. Surg. 96(2), 242-248 (1988).
42. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch. Surg. 127(12), 1416-1450 (1992).
43. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA Intergroup 113), a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J. Clin. Oncol. 25(24), 3719-3725 (2007).
44. Allum WH, Fogarty PJ, Stenning SP, Langley RE, Group NUGCCS. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. Presented at: Gastrointestinal Cancers Symposium 2008. 25-27 January 2008, Orlando, FL, USA. (Presentation 9)
45. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE), FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting Proceedings. Part I. J. Clin. Oncol. 25(18 Suppl.), 4 (2007).
46. Thirion PG, Michiels S, Le Maître A, Tierney J; Group MoCiECC. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18 Suppl.), 4512 (2007).
47. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N. Engl. J. Med. 337(3), 161-167 (1997).
48. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled Phase III trial. Lancet Oncol. 6(9), 659-668 (2005).
49. Lee JL, Park SI, Kim SB et al. A single institutional Phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann. Oncol. 15(6), 947-954 (2004).
50. Tepper E, Krasna M, Niedzwiecki D. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. Proc. Am. Soc. Clin. Oncol. 24, 4012 (2006) (Abstract).
51. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19(2), 305-313 (2001).
52. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335(7), 462-467 (1996).
53. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy of chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8(3), 226-234 (2007).
54. Stahl M, Walz MK, Stuschke M et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: first results of a randomized Phase III trial. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25(18 Suppl.), 4511 (2007).
55. al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J. Clin. Oncol. 15(1), 277-284 (1997).
56. No authors listed. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341(8857), 1359-1362 (1993).
57. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 325(16), 1132-1136 (1991).
58. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325(16), 1127-1131 (1991).
59. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265(10), 1287-1289 (1991).
60. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 5(Suppl. 1), 5-11 (2002).
61. Ye W, Held M, Lagergren J et al. Helicobacte rpylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl Cancer Inst. 96(5), 388-396 (2004).
62. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobarter pylori infection and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol. 5(12), 1413-1417 (2007).
63. The Research Group for Population-Based Cancer Registration in Japan. Annual Reports 1997-2003, 1998-2004. Research Group for Population-Based Cancer Registration, Osaka, Japan.
64. Cancer Statistics: Incidence, Mortality, and Survival 2004. Oshima A, Kuroishi T, Tajima K (Eds). Shinohara Shuppan, Tokyo, Japan (2004).
65. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990-1994 - results and commentary. Ann. Oncol. 14(Suppl. 5), V61-V118 (2003).
66. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph-node dissection for gastric Cancer. N. Engl. J. Med. 340(12), 908-914 (1999).
67. Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345(8952), 745-748 (1995).
68. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 79(9-10), 1522-1530 (1999).
69. Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) raindomised surgical trial. Eur. J. Surg. Oncol. 30(3), 303-308 (2004).
70. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22(11), 2069-2077 (2004).
71. Bunt AM, Hermans J, Smit VT, van de Velde CJ, Fleuren GJ, Bruijn JA. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J. Clin. Oncol. 13(1), 19-25 (1995).
72. Kunisaki C, Akiyama H, Nomura M et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann. Surg. Oncol. 13(5), 659-667 (2006).
73. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 19(6), 1357-1362 (1990).
74. Roviello F, Marrelli D, de Manzoni G et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br. J. Surg. 90(9), 1113-1119 (2003).
75. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 8(1), 1-11 (1982).
76. Cirera L, Balil A, Batiste-Alentorn E et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J. Clin. Oncol. 17(12), 3810-3815 (1999).
77. Coombes RC, Schein PS, Chilvers, CT et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J. Clin. Oncol. 8(8), 1362-1369 (1990).
78. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 35(7), 1059-1064 (1999).
79. Grau JJ, Estape J, Fuster J et al. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J. Clin. Oncol. 16(3), 1036-1039 (1998).
80. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11(8), 1441-1447 (1993).
81. Lise M, Nitti D, Marcher A et al. Final results of a Phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J. Clin. Oncol. 13(11), 2757-2763 (1995).
82. Nakajima T, Nashimoto A, Kitamura M et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 354(9175), 273-277 (1999).
83. Neri B, de Leonardis V, Romano S et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br. J. Cancer 73(4), 549-552 (1996).
84. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007).
85. Macdonald J, Smalley S, Benedetti J. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction Update of the results of Intergroup Study INT-0116 (SWOG 9008). Proc. Am. Soc. Clin. Oncol. 106 (2005) (Abstract).
86. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
87. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
88. Lowy AM, Feig BW, Janjan N et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann. Surg. Oncol. 8(6), 519-524 (2001).
89. Ajani JA, Winter K, Okawara GS et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904), quality of combined modality therapy and pathologic response. J. Clin. Oncol. 24(24), 3953-3958 (2006).
90. Ajani JA, Mansfield PF, Crane CH et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J. Clin. Oncol. 23(6), 1237-1244 (2005).
91. Safran H, Suntharalingam M, Wanebo H, Ng T. Cetuximab, paclitaxel, carboplatin, and radiation for esophageal and gastric cancer. Presented at: Gastrointestinal Cancers Symposium 2006. 26-28 January 2006, San Francisco, CA, USA (Abstract 62).
92. Suntharalingam M, Dipetrillo T, Akerman P, Wanebo B. Cetuximab, paclitaxel, carboplatin, and radiation for esophageal and gastric cancer. Proc. Am. Soc. Clin. Oncol. 24(18 Suppl.), 4029 (2006) (Abstract).
93. Barone C, Corsi DC, Pozzo C et al. Treatment of patients with advanced gastric carcinoma with a 5-fluofouracil-based or a cisptatin-based regimen: two parallel randomized Phase II studies. Cancer 82(8), 1460-1467 (1998).
94. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253(14), 2061-2067 (1985).
95. Cullinan SA, Moertel CG, Wieand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12(2), 412-416 (1994).
96. Ohtsu A, Shimada Y, Shirao K et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21(1), 54-59 (2003).
97. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20(8), 1996-2004 (2002).
98. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15(1), 261-267 (1997).
99. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24(18), 2903-2909 (2006).
100. Cocconi G, Carlini P, Gamboni A et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann. Oncol. 14(8), 1258-1263 (2003).
101. Moehler M, Eimermacher A, Siebler J et al. Randomised Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br. J. Cancer 92(12), 2122-2128 (2005).
102. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15(11), 1585-1595 (2004).
103. Ajani JA, Moiseyenko VM, Tjulandin S et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J. Clin. Oncol. 25(22), 3205-3209 (2007).
104. Ajani JA, Moiseyenko VM, Tjulandin S et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 StudyGroup. J. Clin. Oncol. 25(22), 3210-3216 (2007).
105. Roth AD, Fazio N, Stupp R et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and-fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research. J. Clin. Oncol. 25(22), 3217-3223 (2007).
106. Cavanna L, Artioli F, Codignola C et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am. J. Clin. Oncol. 29(4), 371-375 (2006).
107. Neri B, Pantaleo P, Giommoni E et al. Oxaliplatin, 5-fluorouracil/ leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a Phase II study. Br. J. Cancer 96(7), 1043-1046 (2007).
108. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A Phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as First line therapy for patients with advanced gastric cancer. Acta Oncol. 46(3), 336-341 (2007).
109. Park YH, Lee JL, Ryoo BY et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother. Pharmacol. 61(4), 623-629 (2007).
110. Damstrup L, Wedervang K, Hansen H. Carboplatin, capecitabine and docetaxel (CaCD) in patients with advanced gastric or gastro-esophageal (GE) adenocarcinoma. A single institutional experience. Ann. Oncol. 15(895P) (2004) (Abstract).
111. Hong YS, Song SY, Lee SI et al. A Phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann. Oncol. 15(9), 1344-1347 (2004).
112. Sakamoto J, Chin K, Kondo K et al. Clinical Study Group of Capecitabine. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17(2), 231-236 (2006).
113. Cunningham D, Rao M, Starling N et al. Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 Trial. Proc. Am. Soc. Clin. Oncol. 4017 (2006) (Abstract).
114. Sumpter K, Harper-Wynne C, Cunningham D et al. Report of two protocol planned interim analyses in a randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br. J. Cancer 92(11), 1976-1983 (2005).
115. Chollet P, Schoffski P, Weigang-Kohler K et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur. J. Cancer 39(9), 1264-1270 (2003).
116. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 58(3), 191-197 (2000).
117. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34(11), 1715-1720 (1998).
118. Boku N, Yamamato S, Shirao K et al. Randomized Phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S1 in advanced gastric cancer (JCOG 9912). Proc. Am. Soc. Clin. Oncol. 4513 (2007) (Abstract).
119. Chin K, Iishi H, Imamura H et al. Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized Phase III study (GC0301/TOP-002). Proc. Am. Soc. Clin. Oncol. 4525 (200) (Abstract).
120. Narahara H, Koizumi W, Hara T et al. Randomized Phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS Trial). SPRITIS: S1 plus cisplatin vs S1 in RTC in the treatment of stomach cancer. Proc. Am. Soc. Clin. Oncol. 4514 (2007) (Abstract).
121. Shah MA, Ramanathan RK, Ilson D H et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 2403), 5201-5206 (2006).
122. Enzinger PC, Ryan DP, Regan EM et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Presented at: Gastrointestinal Cancers Symposium 2008. Orlando, FL, USA, 25-27 January 2008.
123. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIR1 in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18(3), 510-517 (2007).
124. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129(2), 504-11 (2005).
125. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92(11), 2076-2083 (2005).
126. Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J. Clin. Oncol. 23(20), 4532-4537 (2005).
127. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am. J. Gastroenterol. 95(1), 17-31 (2000).
128. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann. Surg. 221(1), 59-66 (1995).
129. Yeo CJ, Abrams RA, Grochow, LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann. Surg. 225(5), 621-636 (1997).
130. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Sug. 120(8), 80-903 (1985).
131. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230(6), 776-784 (1999).
132. Smeenk HG, van Eijck CH, Hop WC et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann. Surg. 246(5), 734-740 (2007).
133. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350(12), 1200-1210 (2004).
134. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3), 267-277 (2007).
135. Regine W, Winter K, Abrams R, Safran H, Hoffman J. RTOG 9704 a Phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 2006 (Abstract 4007).
136. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 189(1), 1-7 (1999).
137. No authors listed. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 56(11), 2563-2568 (1985).
138. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl Cancer Inst. 80(10), 751-755 (1988).
139. Klaassen DJ, MacIntyre JM, Carton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 3(3), 373-378 (1985).
140. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2(7626), 865-867 (1969).
141. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8), 1705-1710 (1981).
142. Crane CH, Abbruzzese JL, Evans DB et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1293-1302 (2002).
143. McGinn CJ, Zalupski MM, Shureiqi I et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. oncol. 19(22), 4202-4208 (2001).
144. Wilkowski R, Thoma M, Heinemann V et al. [Radiochemotherapy with gqmcitabine and cisplatin in pancreatic cancer - feasible and
145. Wolff R, Evans D, Gravel D, Lenzi R, Pisters P, Lee J. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 17, 1091 (Abstract) (1998).
146. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 26(18 Suppl.), 4008 (2006).
147. Crane CH, Ellis LM, Abbruzzese JL et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. 24(7), 1145-1151 (2006).
148. Czito BG, Willett CG, Bendell JC et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol. 24(4), 656-662 (2006).
149. Rana V, Krishnan S, Abbruzzese J et al. Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced Pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 24, 4036 (2006) (Abstract).
150. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
151. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94(4), 902-910 (2002).
152. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic Pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509-3516 (2005).
153. Poplin E, Levy D, Berlin J, Rothenberg M, Cella D, Mitchell E. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). Proc. Am. Soc. Clin. Oncol. 4004 (2006) (Abstract).
154. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776-3783 (2004).
155. Heinemann V, Hinke A, Böck S, Labianca R, Louver C. Gemcitabine-based combinations (gem + x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. 2007 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25 (18S), 4515 (2007).
156. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
157. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23(31), 8033-8040 (2005).
158. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol. 22(13), 2610-2616 (2004).
159. Kindler H, Niedzwiecki D, Hollis D. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC), A preliminary analysis of Cancer and Leukemia Gpoup B (CALGB). Proc. Am. Soc. Clin. Oncol. 4508 (2007) (Abstract).
160. Philip P, Benedetti J, Fenoglio-Preiser C. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc. Am. Soc. Clin. Oncol. 4509 (2007) (Abstract).
161. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
162. Sala M, Fuster J, Llovet JM et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 10(10), 1294-1300 (2004).
163. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6), 1434-1440 (1999).
164. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996).
165. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of bepatocellular carcinoma: a randomised trial. Lancet 356(9232), 802-807 (2000).
166. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6), 1394-403 (2001).
167. Okamoto E, Kyo A, Yamanaka N, Tanaka N, Kuwata K. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 95(5), 586-592 (1984).
168. Turcotte JG, Lambert MJ III. Variceal hemorrhage, hepatic cirrhosis, and portacaval shunts. Surgery 73(6), 810-817 (1973).
169. Nagasue N, Uchida M, Makino Y et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105(2), 488-494 (1993).
170. Adam R, Azoulay D, Castaing D et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann. Surg. 238(4), 508-519 (2003).
171. Belghiti J, Cortes A, Abdalla EK et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann. Surg. 238(6), 885-893 (2003).
172. Poon RT. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann. Surg. Oncol. 14(2), 541-547 (2007).
173. Cha CH, Ruo L, Fong Y et al. Resection of Hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann. Surg. 238(3), 315-323 (2003).
174. Hu RH, Ho MC, Wu YM, Yu SC, Lee PH. Feasibility of salvage liver transplantation for patients with recurrent hepatocellular carcinoma. Clin. Transplant. 19(2), 175-180 (2005).
175. Poon KT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann. Surg. 235(3), 373-382 (2002).
176. Lencioni R, Pinto F, Armillotta N et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur. Radiol. 7(4), 514-519 (1997).
177. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197 (1), 101-108 (1995).
178. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228(1), 235-240 (2003).
179. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur. Radiol. 11(6), 914-921 (2001).
180. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 167(3), 7591-768 (1996).
181. Kawai S, Tani M, Okamura J et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother. Pharmacol. 33(Suppl.) S97-102 (1994).
182. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734-1739 (2002).
183. Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology 230(1), 300-302 (2004).
184. Bloomston M, Binitie O, Fraiji E et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am. Surg. 68(9), 827-831 (2002).
185. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 11(7), 767-775 (2005).
186. Perez Saborido B, Meneu JC, Moreno E, Garcia I, Moreno A, Fundora Y. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am. J. Surg. 190(3), 383-387 (2005).
187. Ravaioli M, Grazi GL, Ercolani G et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 78(12), 1780-1786 (2004).
188. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 72(12), 3593-3598 (1993).
189. Stockland AH, Walser EM, Paz-Fumagalli R, McKinney JM, May GR. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate. Cardiovasc. Intervent. Radiol. 30(5), 888-893 (2007).
190. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Thanspl. 12(12), 1761-1769 (2006).
191. Simonetti RG, Liberati A, Angiolini C, Pagliaro I. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 8(2), 117-136 (1997).
192. Yeo W, Mok TS, Zee B et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97(20), 1532-1538 (2005).
193. Leung TW, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5(7), 1676-1681 (1999).
194. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10(4), 355-362 (2003).
195. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28(1), 68-77 (1998).
196. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).
197. Llovet J, Ricci S, Mazzaferro V. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC), Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proc. Am. Soc. Clin. Oncol. LBA1 (2007).
198. Abou-Alfa G, Johnson P, Knox J. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the 2007 meeting of the European Cancer Organization. Eur. J. Cancer Suppl. 5(261), 3500 (2007) (Abstract).
199. Philip PA, Mahoney MR, Allmer C et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23(27), 6657-6663 (2005).
200. Thomas M, Chadha R, Iwasaki M. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). Proc. Am. Soc. Clin. Oncol. 4567 (2007) (Abstract).
201. Zhu A, Sahani D, Tomaso E. A Phase II study of sunitinib in patients with advanced hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol. 4637 (2007) (Abstract).